When administered intravenously in tumor-bearing mice,polySTING selectively targeted CD206+/mannose receptor+ APCs in the TME, resulting in increased cross-presentingCD8+ DCs, infiltrating CD8+ T cells in the TMEas well as maturation across multiple DC subtypes in the tumor-draininglymph node (TDLN). The gene discussed is CD8A; the disease is neoplasm.